A scientific background can be a major asset in a CEO role, not a liability. The core principles of science—making data-driven, rational, and unemotional decisions—translate directly to the business world. This allows for objective choices that align scientific development with the company's business needs.

A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.

The foundation of a successful biotech is scientific innovation. Business leaders who openly respect scientists as the focal point for value creation can build trusting, effective relationships that accelerate development and commercialization.

In the early stages, a biotech CEO's role is primarily scientific leadership and storytelling to attract investors. As the company and market mature, the role shifts. Effective CEOs must then become adaptable strategists, staying true to their core vision while responding to the dynamic industry environment.

Kevin Pojasek credits his effectiveness to a deliberate 12-year journey through diverse roles—investing, company creation, research, and clinical operations. This broad experience allows a leader to understand how all parts of the company, from high-level strategy to detailed science, fit together.

Recognizing that business leaders—not scientists—often set research priorities, Jonathan Steckbeck intentionally earned an MBA before his PhD. This nontraditional path gave him the commercial acumen to found a company where he could direct both the scientific and business strategy from day one.

A critical step for technical founders is honestly assessing their non-scientific weaknesses. Professor Waranyoo Phoolcharoen knew she couldn't be both CTO and CEO, so she deliberately sought a co-founder with strong business, finance, and marketing skills to complement her technical expertise.

Resolution Therapeutics' CEO builds his team with leaders from varied backgrounds across different diseases and drug modalities. He believes this diversity creates more robust problem-solving, as challenges that are novel in one area may have been solved in another, enabling faster and more informed decisions.

Luba Greenwood argues that unlike in tech, many biotech CEOs lack P&L experience. In today's cash-constrained market, CEOs need to be able to build financial models and understand finance deeply to be effective, a skill she personally developed after transitioning from law and science.